journal article·2018-02-17Open access

RETRACTED ARTICLE: Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer

Niyaz Ahmad, Md Aftab Alam, Rizwan Ahmad, Atta Abbas Naqvi, Farhan Jalees Ahmad

This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Abstract

Docetaxel (DTX), a cytotoxic taxane, is a poor water-soluble drug and exhibits less oral bioavailability. Current research investigates the effective transport, for DTX-loaded chitosan (CS)-coated-poly-lactide-co-glycolide (PLGA)-nanoparticles (NPs) (DTX-CS-PLGA-NPs) and DTX-PLGA-NPs as well as a novel third-generation P-gp inhibitor i.e. GF120918 (Elacridar), across intestinal epithelium with its successive uptake by the tumour cells in an in vitro model. The prepared NPs showed a spherical shape particle size i.e. <123.96 nm with polydispersity index (PDI) of <0.290 whereas for CS-coated NPs, the zeta potential was converted from negative to positive value along with a small modification in particle size distribution. The entrapment efficiency observed for DTX-CS-PLGA-NPs was 74.77%, whereas the in vitro release profile revealed an initial rapid DTX release followed by a sustained release pattern. For apparent permeability, DTX-CS-PLGA-NPs and DTX-PLGA-NPs along with GF120918 showed a five-fold (p < .01) and 2.2-fold enhancement, respectively, as observed in rat ileum permeation study. Similarly, for pharmacokinetic (PK) studies, higher oral bioavailability was observed from DTX-CS-PLGA-NPs (5.11-folds) and DTX-PLGA-NPs (3.29-folds) as compared with DTX-suspension (DTX-S). Cell uptake studies on A549 cells as performed for DTX-CS-PLGA-NPs and DTX-PLGA-NPs loaded with rhodamine 123 dye, exhibited enhanced uptake as compared with plain dye solution. The enhanced uptake for DTX-CS-PLGA-NPs and DTX-PLGA-NPs formulations in the presence of GF120918 was confirmed further with the help of confocal laser scanning microscopic images (CLSM). The potential of the third-generation novel P-gp inhibitor (GF120918) investigated for the effective delivery of DTX as well as investigation of permeability and uptake studies whereby a strong potential of GF120918 for effective oral delivery was established.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Department of Pharmaceutics, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India;

Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Nanomedicine Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

References (72)

Show source-provided references
1. 10.1038/nrc156610.1038/nrc1566 ↗
2. 10.1146/annurev.bioeng.9.060906.15202510.1146/annurev.bioeng.9.060906.152025 ↗
3. 10.1002/adhm.20140075110.1002/adhm.201400751 ↗
4. 10.7150/thno.1418410.7150/thno.14184 ↗
5. 10.1021/bm060065f10.1021/bm060065f ↗
6. 10.1016/j.colsurfb.2014.07.00410.1016/j.colsurfb.2014.07.004 ↗
7. 10.1016/j.ijpharm.2016.01.05410.1016/j.ijpharm.2016.01.054 ↗
8. 10.1016/j.ijbiomac.2016.06.00110.1016/j.ijbiomac.2016.06.001 ↗
9. 10.1007/s11051-015-3121-310.1007/s11051-015-3121-3 ↗
10. 10.1016/j.carbpol.2016.07.11910.1016/j.carbpol.2016.07.119 ↗
11. Liang Q · Discov Med · 2017 · 23 · 27
12. 10.1002/jcp.2586910.1002/jcp.25869 ↗
13. Rui H · Acta Biomaterialia · 2017
14. 10.1016/j.reactfunctpolym.2004.02.01810.1016/j.reactfunctpolym.2004.02.018 ↗
15. 10.1016/j.ijbiomac.2016.11.09810.1016/j.ijbiomac.2016.11.098 ↗
16. 10.1016/j.biomaterials.2013.04.05210.1016/j.biomaterials.2013.04.052 ↗
17. 10.3816/CBC.2008.s.00210.3816/CBC.2008.s.002 ↗
18. 10.1111/j.1742-7843.2008.00351.x10.1111/j.1742-7843.2008.00351.x ↗
19. 10.1158/1535-7163.MCT-08-106810.1158/1535-7163.MCT-08-1068 ↗
20. 10.1056/NEJM19950413332150710.1056/NEJM199504133321507 ↗
21. 10.1155/2012/98921410.1155/2012/989214 ↗
22. Syrigos KN · Anticancer Res · 2002 · 22 · 3583
23. Schöffski P · Anticancer Res · 1998 · 18 · 4751
24. 10.1200/JCO.2001.19.4.116010.1200/JCO.2001.19.4.1160 ↗
25. 10.1016/S0076-6879(96)72018-910.1016/S0076-6879(96)72018-9 ↗
26. 10.1016/j.ijpharm.2006.06.02310.1016/j.ijpharm.2006.06.023 ↗
27. Noori Koopaei M · Iran J Pharm Res · 2014 · 13 · 819
28. 10.3109/02652048.2012.66895910.3109/02652048.2012.668959 ↗
29. 10.1248/bpb.34.27810.1248/bpb.34.278 ↗
30. 10.1016/j.jconrel.2009.08.01510.1016/j.jconrel.2009.08.015 ↗
31. 10.1016/j.jconrel.2016.07.04810.1016/j.jconrel.2016.07.048 ↗
32. Terwogt JMM · Clin Cancer Res · 1999 · 5 · 3379
33. 10.1023/A:102228642243910.1023/A:1022286422439 ↗
34. 10.1016/S0960-894X(99)00030-X10.1016/S0960-894X(99)00030-X ↗
35. Dantzig AH · J Pharmacol Exp Ther · 1999 · 290 · 85410.1016/S0022-3565(24)34974-2 ↗
36. 10.1023/A:100648700381410.1023/A:1006487003814 ↗
37. Newman MJ · Cancer Res · 2000 · 60 · 2964
38. Maliepaard M · Clin Cancer Res · 2001 · 7 · 935
39. 10.1177/10732748030100020710.1177/107327480301000207 ↗
40. Hyafil F · Cancer Res · 1993 · 53 · 4595
41. 10.1054/bjoc.2000.154310.1054/bjoc.2000.1543 ↗
42. Mokale VJ · SAJ Pharm Pharmacol · 2014 · 1 · 10
43. 10.1016/j.msec.2015.11.06110.1016/j.msec.2015.11.061 ↗
44. 10.1002/jps.1014310.1002/jps.10143 ↗
45. 10.1023/A:102509693060410.1023/A:1025096930604 ↗
46. 10.1002/dta.147210.1002/dta.1472 ↗
47. 10.1016/j.ejmech.2006.01.01310.1016/j.ejmech.2006.01.013 ↗
48. 10.1016/0006-291X(91)91647-U10.1016/0006-291X(91)91647-U ↗
49. 10.1016/j.ijpharm.2004.11.02710.1016/j.ijpharm.2004.11.027 ↗
50. 10.1016/S0378-5173(96)04697-210.1016/S0378-5173(96)04697-2 ↗
51. 10.1016/j.ejpb.2007.01.01210.1016/j.ejpb.2007.01.012 ↗
52. 10.3109/03639045.2013.77558110.3109/03639045.2013.775581 ↗
53. 10.1016/j.jconrel.2007.01.00810.1016/j.jconrel.2007.01.008 ↗
54. 10.1016/j.jconrel.2007.01.01610.1016/j.jconrel.2007.01.016 ↗
55. 10.1002/jps.2341710.1002/jps.23417 ↗
56. 10.1208/s12249-013-9943-310.1208/s12249-013-9943-3 ↗
57. 10.1016/j.jcis.2010.10.02410.1016/j.jcis.2010.10.024 ↗
58. Aydin RST · J Nanomater · 2012 · 2012 · E31396110.1155/2012/313961 ↗
59. Ahmad N · Drug Deliv · 2016 · 23 · 209510.1080/10717544.2016.1212950 ↗
60. 10.1186/1556-276X-6-26010.1186/1556-276X-6-260 ↗
61. Zhang W · Biomacromolecules · 2010 · 1:1331
62. 10.2217/nnm.09.2810.2217/nnm.09.28 ↗
63. Masumi H · J Cancer Res · 2001 · 92 · 459
64. 10.1002/adfm.20160598510.1002/adfm.201605985 ↗
65. 10.1002/ppsc.20140004810.1002/ppsc.201400048 ↗
66. 10.1016/j.actbio.2015.11.03110.1016/j.actbio.2015.11.031 ↗
67. 10.1016/j.jcis.2015.11.00110.1016/j.jcis.2015.11.001 ↗
68. 10.1039/C5RA09042C10.1039/C5RA09042C ↗
69. 10.1021/mp300202c10.1021/mp300202c ↗
70. 10.1016/j.ejps.2014.04.01410.1016/j.ejps.2014.04.014 ↗
71. 10.1007/s11095-008-9763-410.1007/s11095-008-9763-4 ↗
72. 10.1002/jps.2115510.1002/jps.21155 ↗